Other proposed mechanisms of hypercoagulability in azotemic patients include increased levels of fibrinogen, coagulation factors II, XIIa, and VIIa, activated protein C complex, and thrombin-antithrombin complexes. This evidence concerns the gene F2 and thrombophilia.